Day One Biopharmaceutical 株価情報 (NASDAQ: DAWN)

最新ニュース Day One Biopharmaceutical (NASDAQ:DAWN) 株価情報

Day One Biopharmaceutical

Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, kinase inhibitor.

Day One Biopharmaceuticals, Inc. - Common Stock

Day One Biopharmaceuticals Inc

Dawn Protocol

DAWNRAYS PHARM HLDGS LTD by Dawnrays Pharmaceutical Holdings, Ltd.

Ooredoo Qatar taps Nokia 5G Standalone Core to deliver advanced network services and generate new revenue streams
<ul>
<li>Nokia will deliver a modernized core network that enables Ooredoo Qatar to offer more advanced services using network slicing.</li>
<li>Network will generate new consumer and enterprise revenue streams across industries such as ports, mining and natural gas.</li>
</ul>

News

Ooredoo Qatar Selects Nokia 5G Standalone Core To Power Advanced Network Services And Drive New Revenue Streams

Nokia and Cellcard upgrade residential fiber broadband network in Cambodia
<ul>
<li>Cellcard deploys Nokia's next-generation XGS-PON solution, providing multi-gigabit broadband access to homes and businesses across Cambodia.</li>
<li>Cellcard uses Nokia's Lightspan and Altiplano solutions to automate and increase the performance of its residential fiber broadband network.&nbsp;&nbsp;</li>
<li>The upgraded network will enable Cellcard to provide enhanced broadband services and support new high-speed, low-latency applications such as Augmented Reality (AR) and Virtual Reality (VR).</li>
</ul>

Reported Earlier, Nokia And Cellcard Modernize Cambodia's Broadband With XGS-PON, Delivering Multi-Gigabit Speeds Nationwide

This strategic move reinforces Envirotech's commitment to expanding U.S. manufacturing, strengthening fleet services, and supporting the growing demand for commercial electric vehicles (EVs). Envirotech plans to open its new corporate headquarters and manufacturing facility in the first quarter of 2025.
The new Houston headquarters and manufacturing facility will serve as a centralized hub for corporate leadership, manufacturing, fleet sales, engineering, and service operations, positioning Envirotech for continued growth and long-term success in the commercial EV market.

EVTV

Reported Earlier, Envirotech Vehicles Relocates Headquarters To Houston, Expands U.S. Manufacturing With New 86,000-Sq.-Ft. Facility

Reported Earlier, SDG&E, A Sempra Subsidiary, Becomes First California Utility To Earn CAL/OSHA VPP Safety Certification

Earnings

Barclays Delivered A RoTE Of 7.5% In Q4 2024 And 10.5% In FY24

Sony Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SONY#NYSE">SONY</a>) reported quarterly earnings of $0.41 per share. This is a 2.5 percent increase over earnings of $0.40 per share from the same period last year. The company reported $28.970 billion in sales this quarter. This is a 14.20 percent increase over sales of $25.367 billion the same period last year.

Sony Group Corporation American Depositary Shares

SONY

Sony Group Q3 2024 GAAP EPS $0.41 Up From $0.40 YoY, Sales $28.970B Up From $25.367B YoY

Guidance

Barclays 2025 Outlook: Sees Barclays Group NII Excluding Barclays Investment Bank And Head Office Of £12.2B; Expects RoTE Of 11% In 2025

IPOs

Reported Earlier, TEN Holdings Prices $10M Initial Public Offering Of 1,667,000 Common Shares At $6/Share, Shares To Trade On NASDAQ Under "XHLD"

Earnings Misses

Barclays Q4 2024 GAAP EPS $0.34 Misses $0.35 Estimate, Sales $8.927B Up From $6.950B YoY

The CNN Money Fear and Greed index showed a decline in the overall market sentiment, with the index in the &#8220;Fear&#8221; zone on Wednesday.
U.S. stocks settled mostly lower on Wednesday, with the Dow Jones index falling more than 200 points during the session following the release of inflation data.
The headline CPI rose 3% year over year in January, surpassing both December&#8217;s 2.9% reading and economist forecasts of 2.9%. On a monthly basis, inflation increased 0.5%, outpacing expectations of 0.3% and accelerating from December&#8217;s 0.4% gain. This marked the fastest monthly inflation rate since August 2023.
Shares of some megacap tech stocks, including Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) and Alphabet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>) settled lower on Wednesday. However, Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) shares jumped more than 2% during the session after the electric vehicle maker tumbled 6.3% on Tuesday, reaching oversold levels and extending its losing streak to five consecutive sessions.
CVS Health Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) shares surged around 15% on Wednesday after the company reported better-than-expected results for its fourth quarter.
Most sectors on the S&amp;P 500 closed on a negative note, with materials, energy, and real estate stocks recording losses on Wednesday. However, consumer staples and communication services stocks bucked the overall market trend, closing the session higher.
The Dow Jones closed lower by around 225 points to 44,368.56 on Wednesday. The S&amp;P 500 fell 0.27% to 6,051.97, while the Nasdaq Composite rose 0.03% at 19,649.95 during Wednesday's session.
Investors are awaiting earnings results from Deere &amp; Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>), GE HealthCare Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NASDAQ">GEHC</a>), and Coinbase Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) today.
What Is CNN Business Fear &amp; Greed Index?
At a current reading of 43.8, the index remained in the &#8220;Fear&#8221; zone on Wednesday, versus a prior reading of 44.
The Fear &amp; Greed Index is a measure of the current market sentiment. It is based on the premise that higher fear exerts pressure on stock prices, while higher greed has the opposite effect. The index is calculated based on seven equal-weighted indicators. The index ranges from 0 to 100, where 0 represents maximum fear and 100 signals maximum greediness.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43656665/wall-streets-most-accurate-analysts-weigh-in-on-3-tech-telecom-stocks-with-over-3-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Tech &amp; Telecom Stocks With Over 3% Dividend Yields</a></li>
</ul>
Photo courtesy: Shutterstock

Pre-Market Outlook

Markets

Trading Ideas

AMZN

COIN

GEHC

GOOG

GOOGL

TSLA

Dow Dips More Than 200 Points Following Inflation Report, Megacap Tech Stocks Edge Lower: Greed Index In 'Fear' Zone

Reported Earlier, Bell Prices $1B And $1.25B Fixed-to-Fixed Rate Notes, Offering Interest Resets Every Five Years

Zebra Technologies Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBRA#NASDAQ">ZBRA</a>) will release its fourth-quarter financial results, before the <a href="https://www.benzinga.com/quote/zbra/earnings">opening bell, on Thursday, Feb. 13, 2025.</a>
Analysts expect the Lincolnshire, Illinois-based company to report quarterly earnings at $3.94 per share, up from $1.71 per share in the year-ago period. Zebra Technologies projects quarterly revenue of $1.32 billion, compared to $1.01 billion a year earlier, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Jan. 7, Zebra Technologies announced plans to acquire Photoneo, a leading developer and manufacturer of 3D machine vision solutions.
Zebra Technologies shares fell 0.4% to close at $352.92 on Wednesday.
Benzinga readers can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let's have a look at how Benzinga's most-accurate <a href="https://www.benzinga.com/quote/GBX/analyst-ratings">analysts have rated the company</a> in the recent period.
<ul>
<li>Truist Securities analyst Jamie Cook maintained a Hold rating and raised the price target from $408 to $409 on Jan. 16, 2025. This analyst has an accuracy rate of 70%.</li>
<li>Morgan Stanley analyst Meta Marshall maintained an Equal-Weight rating and increased the price target from $400 to $427 on Dec. 17, 2024. This analyst has an accuracy rate of 76%.</li>
<li>Barclays analyst Tim Long maintained an Equal-Weight rating and raised the price target from $347 to $407 on Oct. 31, 2024. This analyst has an accuracy rate of 74%.</li>
<li>TD Cowen analyst Joseph Giordano maintained a Buy rating and increased the price target from $380 to $425 on Oct. 30, 2024. This analyst has an accuracy rate of 66%.</li>
<li>Baird analyst Richard Eastman maintained an Outperform rating and boosted the price target from $380 to $415 on Oct. 30, 2024. This analyst has an accuracy rate of 78%.</li>
</ul>
Considering buying ZBRA stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="626" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13023754/image-109-1024x626.png" alt="" class="wp-image-780382" style="width:692px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13023754/image-109-1024x626.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13023754/image-109-300x183.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13023754/image-109-768x469.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/13023754/image-109.png 1083w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43656665/wall-streets-most-accurate-analysts-weigh-in-on-3-tech-telecom-stocks-with-over-3-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Tech &amp; Telecom Stocks With Over 3% Dividend Yields</a></li>
</ul>

Price Target

Analyst Ratings

ZBRA

Zebra Technologies Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts

With U.S. stock futures trading higher this morning on Thursday, some of the stocks that may grab investor focus today are as follows:
<ul>
<li>Wall Street expects Deere &amp; Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>) to report quarterly earnings at $3.11 per share on revenue of $7.70 billion before the opening bell, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>. Deere shares fell 0.1% to $476 in after-hours trading.</li>
<li>Fastly, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSLY#NYSE">FSLY</a>) reported a fourth-quarter loss of 3 cents per share, down from earnings of 1 cent per share in the prior year's quarter. Quarterly revenue came in at $140.58 million, beating the $138.27 million analyst consensus estimate. Fastly expects first-quarter losses of between 9 cents and 5 cents per share, versus the loss of 1 cent estimate, and revenue in a range of $136 million to $140 million, versus the $137.05 million estimate. Fastly shares dipped 21.5% to $7.91 in the after-hours trading session.</li>
<li>Analysts are expecting GE HealthCare Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEHC#NASDAQ">GEHC</a>) to post quarterly earnings at $1.26 per share on revenue of $5.33 billion. The company will release earnings before the markets open. GE HealthCare shares fell 0.1% to $85.82 in after-hours trading.</li>
</ul>
Check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here</a>
<ul>
<li>HubSpot, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBS#NYSE">HUBS</a>) reported stronger-than-expected results for its fourth quarter. The company said it sees first-quarter revenue of between $697 million and $699 million, versus the $705.71 million estimate, and EPS of between $1.74 and $1.76, versus the $2.00 estimate. HubSpot shares gained 5% to $825.00 in the after-hours trading session.</li>
<li>Analysts expect Coinbase Global, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>) to post quarterly earnings at $1.81 per share on revenue of $1.83 billion after the closing bell. Coinbase shares gained 3% to $283.10 in after-hours trading.</li>
</ul>
Check This Out: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43656665/wall-streets-most-accurate-analysts-weigh-in-on-3-tech-telecom-stocks-with-over-3-dividend-yields">Wall Street&#8217;s Most Accurate Analysts Weigh In On 3 Tech &amp; Telecom Stocks With Over 3% Dividend Yields</a></li>
</ul>
Photo courtesy: Shutterstock

Long Ideas

FSLY

HUBS

Deere, GE HealthCare And 3 Stocks To Watch Heading Into Thursday

EV giant Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) is offering discounts up to $6000 on inventory <a href="https://www.benzinga.com/topic/cybertruck">Cybertrucks</a> in the U.S.
What Happened: The company is offering discounts up to $6000 on foundation series Cybertrucks and $5,100 on non-foundation series Cybertrucks in its inventory.
The offers apply to new 2024 model year vehicles.
In January, the company only offered discounts of <a href="https://www.benzinga.com/tech/25/01/43021093/tesla-offers-discounts-up-to-2000-on-new-inventory-cybertrucks">as much as $2000 on non-foundation series </a>Cybertrucks. 
Why It Matters:&nbsp;The Cybertruck is one of Tesla's more premium offerings. The vehicle starts at $79,990 for the base all-wheel drive variant and at $99,990 for the more premium Cyberbeast variant.
According to data from automotive research firm Kelley Blue Book, the Cybertruck was Tesla's third best-selling vehicle in the U.S. in 2024, after its mass-market offerings Model 3 and Model Y.
The company sold&nbsp;<a href="https://www.benzinga.com/25/01/42967593/cybertruck-sales-rise-in-2024-weighed-down-on-tesla-model-s-deliveries-in-us-shows-data" target="_blank" rel="noreferrer noopener">38,965 units in the 12 months through the end of December</a>, significantly higher than the number of Model S or Model X sold in the country.
Tesla made only the foundation series Cybertrucks for the first few months of deliveries. In October, Tesla started selling the <a href="https://www.benzinga.com/25/01/42891397/non-foundation-series-cheaper-cybertrucks-join-tesla-inventory">regular version of Cybertruck </a>priced about $20,000 lower than the foundation series. The foundation series refers to a limited and pricier edition of the Cybertruck with laser-etched foundation series badges and premium accessories.
Check out more of Benzinga&#8217;s Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43650738/nasa-alters-timelines-to-expedite-return-of-astronauts-sunita-williams-butch-wilmore-stranded-at-iss-for-over-8-months">NASA Alters Timelines To Expedite Return Of Astronauts Sunita Williams, Butch Wilmore Stranded At Space Station For Over 8 Months</a></li>
</ul>
Photo courtesy: Shutterstock

Tech

Tesla Hikes Discounts On Cybertrucks By 3X To $6000 As It Looks To Clear 2024 Inventory

A suspected gas explosion at the Shin Kong Mitsukoshi shopping mall in Taichung, Taiwan&#8217;s Situn District killed one person and critically injured five others on Wednesday morning, according to local authorities. Emergency responders are continuing rescue efforts and investigating the cause.
The explosion, which occurred on the mall&#8217;s 12th floor at 11:33 a.m. local time, also sent at least 12 people to hospitals, <a href="https://www.taipeitimes.com/News/front/archives/2025/02/13/2003831827">reported</a> Taipei Times.
Reports suggest a possible gas leak while a restaurant was changing a gas canister or ongoing renovations in the food court.
The Taichung Fire Bureau stated that the exact cause remains under investigation.
Police are assisting with evacuations and traffic control as officials warn motorists to avoid the area. 
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/02/43681236/bitcoin-ethereum-dogecoin-spike-amid-hotter-than-expected-inflation-numbers-eths-decisive-move-above-3000-could-restore-confidence-says-analyst">Bitcoin, Ethereum, Dogecoin Spike Amid Hotter-Than-Expected Inflation Numbers: ETH&#8217;s Decisive Move Above $3,000 Could Restore Confidence, Says Analyst</a></li>
</ul>
Image Via Shutterstock

Global

Taiwan Mall Explosion Kills One, Injures Several — Investigation Underway

Macro Economic Events

Econ #s

Economics

Germany Consumer Price Index (YoY) For January 2.3% Vs. 2.3% Est.; 2.6% Prior

Germany Consumer Price Index (MoM) For January -0.2% Vs. -0.2% Est.; 0.5% Prior

U.K. Trade Balance Non-EU For December -6.10B Vs. -7.19B (Revised) Prior

U.K. Trade Balance For December -17.45B Vs. -18.60B Est.; -18.90B (Revised) Prior

U.K. Monthly Gross Domestic Product 3M/3M Change For December 0.1% Vs. -0.1% (Revised) Prior

In a report released yesterday, Joseph Catanzaro from Piper Sandler assigned a Buy rating to Day One Biopharmaceuticals (DAWN – Research Report), w...

Day One Biopharmaceuticals (DAWN) Gets a Buy from Piper Sandler

JonesResearch lowered the firm's price target on Day One Biopharmaceuticals (DAWN) to $34 from $39 and keeps a Buy rating on the shares. The firm s...

Day One price target lowered to $34 from $39 at JonesResearch

Day One Biopharmaceuticals ($DAWN) enjoyed a strong third quarter in 2024, significantly beating top-and-bottom-line expectations driven by robust ...

Day One Biopharmaceuticals (DAWN) Posts Stellar Q3 but with Extreme Concentration Risk

Day One Biopharmaceuticals: Sales Figures In The Crosshairs... And What Else?

Top 5 Commercial Biotech Buyout Candidates: Day One Biopharmaceuticals (No. 5)

Day One Biopharmaceuticals ( ($DAWN) ) just unveiled an announcement. Day One Biopharmaceuticals announced preliminary results for 2024, reporting ...

Day One Biopharmaceuticals Reports 2024 Financial Results

Needham analyst Ami Fadia has maintained their bullish stance on DAWN stock, giving a Buy rating on January 7. Ami Fadia has given his Buy rating d...

Optimistic Outlook for Day One Biopharmaceuticals: Strong Sales Performance and Promising Pipeline Support Buy Rating

In a report released today, Alec Stranahan from Bank of America Securities maintained a Buy rating on Day One Biopharmaceuticals (DAWN – Research R...

Bank of America Securities Reaffirms Their Buy Rating on Day One Biopharmaceuticals (DAWN)

Day One Biopharmaceuticals: A Successful Launch In Pediatric Cancer

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Day One Biopharmaceuticals (DAWN – Research Report),...

Analysts Are Bullish on These Healthcare Stocks: Day One Biopharmaceuticals (DAWN), Health Catalyst (HCAT)

ABBV

ALNY

AMGN

ARGX

AXSM

BIIB

BNTX

CSLLY

DAWN

GILD

HCAT

IPSEF

IPSEY

NVSEF

REGN

RHHBF

RHHBY

RHHVF

VRTX

Press Releases

Day One Announces Oversubscribed $175.0 Million Private Placement

Day One Reports Second Quarter 2024 Financial Results and Corporate Progress

Day One to Report Third Quarter 2024 Financial Results Wednesday, October 30, 2024

Day One Reports Third Quarter 2024 Financial Results and Corporate Progress

Day One to Participate in the Piper Sandler 36th Annual Healthcare Conference

Management

Day One Announces Retirement of Dr. Samuel Blackman, Co-Founder and Head of Research & Development

Day One to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Day One Reports Preliminary 2024 OJEMDA™ Net Product Revenue and Highlights 2025 Corporate Priorities

Biotech Investing: How PRVs Can Unlock Major Opportunities

Day One to Report Fourth Quarter and Full-Year 2024 Financial Results Tuesday, February 25, 2025

Comments

Day One Biopharmaceutical

ニュース

最新ニュース Day One Biopharmaceutical (NASDAQ:DAWN) 株価情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル